1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Everest Medicines Limited
  6. News
  7. Summary
    1952   KYG3224E1061

EVEREST MEDICINES LIMITED

(1952)
  Report
Delayed Hong Kong Stock Exchange  -  05/20 04:08:13 am EDT
21.40 HKD   -1.83%
04/07Everest Medicines to Form Vaccine JV With China Resources Pharmaceutical
MT
04/06Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
CI
04/05Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines Program

12/20/2021 | 06:55am EDT

Everest Medicines and Providence Therapeutics ("Providence") announced that their COVID-19 vaccine, PTX-COVID19-B, has been recommended by an independent advisory group to be part of the WHO Solidarity Trial Vaccines ("STV") clinical trial. PTX-COVID19-B is a potentially best-in-class lipid nanoparticle-formulated mRNA vaccine with strong immunogenicity and tolerability profiles. The STV is an international, randomized clinical trial designed to rapidly evaluate the efficacy and safety of promising new candidate vaccines. Vaccines are selected by an independent vaccine prioritization advisory group composed of leading scientists and experts based on pre-defined criteria, including their safety and proven potential for effectiveness, stability of the vaccine, whether they can be produced quickly for global distribution, and the ease with which they can be given to individuals.


© S&P Capital IQ 2021
All news about EVEREST MEDICINES LIMITED
04/07Everest Medicines to Form Vaccine JV With China Resources Pharmaceutical
MT
04/06Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent ..
CI
04/05Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent ..
PR
03/31Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan
CI
03/28Everest Medicines Narrows Loss as General, Administrative Expenses Fall in 2021
MT
03/28TRANSCRIPT : Everest Medicines Limited, 2021 Earnings Call, Mar 29, 2022
CI
03/28Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021
PR
03/28Everest Medicines Limited Appoints Leah Liu as Joint Company Secretary
CI
03/21Calliditas Therapeutics AB - Updated regulatory plans for NEFECON in China
AQ
03/18Calliditas Therapeutics Says Partner Everest Medicines Plans to File Nefecon NDA in Chi..
MT
More news
Analyst Recommendations on EVEREST MEDICINES LIMITED
More recommendations
Financials
Sales 2022 193 M 28,8 M 28,8 M
Net income 2022 -1 095 M -164 M -164 M
Net cash 2022 873 M 130 M 130 M
P/E ratio 2022 -4,93x
Yield 2022 -
Capitalization 5 422 M 810 M 810 M
EV / Sales 2022 23,6x
EV / Sales 2023 2,85x
Nbr of Employees 405
Free-Float 100%
Chart EVEREST MEDICINES LIMITED
Duration : Period :
Everest Medicines Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVEREST MEDICINES LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 18,25 CNY
Average target price 34,67 CNY
Spread / Average Target 90,0%
EPS Revisions
Managers and Directors
Kerry Levan Blanchard Chief Executive Officer & Executive Director
Ian Ying Woo President, CFO & Executive Director
Wei Fu Executive Chairman
Xinhui Hu Chief Technology Officer
Jennifer Yang Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
EVEREST MEDICINES LIMITED-38.51%825
CSL LIMITED-5.75%93 171
SAMSUNG BIOLOGICS CO.,LTD.-10.52%44 721
BIOGEN INC.-19.52%28 278
WUXI BIOLOGICS (CAYMAN) INC.-43.60%28 063
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.71%21 889